ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place from April 17 to April 22, 2026, in San Diego, California, USA.

The data to be presented involve three of the company's drug candidates. These include the novel Class 1 BCR-ABL inhibitor olverembatinib (marketed as Nirlisq®; R&D code: HQP1351), the FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the EED inhibitor APG-5918.

The AACR Annual Meeting serves as a critical platform for advancing oncology. It brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer research. The meeting comprehensively showcases cutting-edge science and medicine, covering areas from population science and prevention to cancer biology, translational and clinical research, and survivor care and advocacy.